Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2023-03-22 Annual Report
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Infant Bacterial Therapeutics AB Årsredovisning 2022' (Annual Report 2022). It contains a comprehensive table of contents including management reports, financial statements (Resultaträkning, Balansräkning, Kassaflödesanalys), notes, and an audit report (Revisionsberättelse). It covers the full fiscal year of 2022 and provides detailed financial and operational performance data, fitting the definition of an Annual Report (10-K). FY 2022
2023-03-22 Swedish
Annual Report 2022
Annual Report Classification · 100% confidence The document is explicitly titled 'Infant Bacterial Therapeutics AB Annual Report 2022'. It contains a comprehensive overview of the company's activities, a message from the CEO, a detailed Director's Report, audited financial statements (Income Statement, Balance Sheet, Cash Flows), and an Auditor's Report. It covers the full fiscal year from January 1 to December 31, 2022, and meets all criteria for a formal Annual Report. FY 2022
2023-03-22 English
Audit Report / Information 2022
Audit Report / Information Classification · 95% confidence The document is titled "Bokslutskommuniké 1 januari – 31 december 2022" (Year-end report communication 1 January – 31 December 2022) and presents detailed financial results for the fourth quarter and the full year 2022, including key figures, management commentary, and financial tables. The content is comprehensive, covering operational highlights, financial performance, and future outlook for the entire fiscal year. This structure and content strongly indicate a full-year financial report, which corresponds to the Annual Report (10-K) definition, although the specific filing might be a local equivalent or a preliminary release preceding the formal 10-K filing. Given the depth of the financial data presented (full P&L, balance sheet items, cash flow), it is more substantial than a mere Earnings Release (ER) or Interim Report (IR). Since the document covers the full fiscal year (Jan-Dec 2022) and contains detailed financial statements and management discussion, it aligns best with the '10-K' category, representing the annual financial disclosure, even if the Swedish title translates more literally to an 'Year-End Communication'. The document length (45,172 chars) confirms it is a substantial report, not a short announcement (ruling out RPA/RNS based on length/content). FY 2022
2023-02-10 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1-December 31, 2022' and contains comprehensive financial statements, including income statements, cash flow data, and management commentary for the fourth quarter and the full year 2022. It provides detailed financial tables and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q4 2022
2023-02-10 English
Annual Report 2021
Annual Report Classification · 100% confidence The document is explicitly titled 'Årsredovisning 2021' (Annual Report 2021) for Infant Bacterial Therapeutics AB. It contains a comprehensive overview of the company's activities, financial statements (Resultaträkning, Balansräkning, Kassaflödesanalys), notes, and an audit report (Revisionsberättelse) for the fiscal year 2021. It meets all criteria for a full annual report. FY 2021
2023-01-27 Swedish
Annual Report 2021
Annual Report Classification · 100% confidence The document is explicitly titled 'Infant Bacterial Therapeutics AB Annual Report 2021'. It contains a comprehensive table of contents, including a Director's Report, Income Statement, Balance Sheet, Cash Flow Statement, Notes, and Auditor's Report, covering the fiscal year from January 1 to December 31, 2021. It is a full annual report, not an announcement or a summary. FY 2021
2023-01-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.